United Therapeutics Corporation UTHR
601.32 USD +5.19 (+0.87%)
At closeNov 3, 2026, 4:42 PM EST
601.32 0.00 0.00%
After hours · Nov 3, 4:42 PM ET
596.14 Day range 606.16
430.02 52-week range 609.99
- YTD
- +23.41%
- 1 year
- +37.08%
Analyst view
Consensus: buy
Buy
Price target (mean) 670.93 +11.6% upside
Now 601.32
- Target (low)
- 368.00
- Target (mean)
- 670.93
- Target (high)
- 850.00
Ratings (0m) 15 11 buy · 3 hold · 1 sell
- Strong buy3
- Buy8
- Hold3
- Sell1
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 15
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 6.04 | 4.40 – 7.26 | 7.16 | -15.6% | 781.14M | -2.3% | 14 |
| Next quarter | 7.43 | 3.05 – 10.15 | 7.70 | -3.5% | 833.64M | +5.5% | 14 |
| Current year | 26.63 | 22.65 – 30.81 | 27.86 | -4.4% | 3.18B | -0.1% | 14 |
| Next year | 31.14 | 21.87 – 38.08 | 26.63 | +17.0% | 3.60B | +13.4% | 14 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 22, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 19, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 7, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 1, 2026 | BTIG | Upgrade | Neutral | Buy |
| Sep 24, 2026 | Goldman Sachs | Initiated | — | Sell |
| Aug 6, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 23, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 10, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 7, 2026 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Apr 10, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 31, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Mar 30, 2026 | TD Cowen | Maintained | Buy | Buy |
| Mar 23, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 12, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Mar 5, 2026 | UBS | Maintained | Buy | Buy |
| Feb 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 26, 2026 | TD Cowen | Maintained | Buy | Buy |
| Feb 26, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 26, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 26, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Jan 6, 2026 | UBS | Maintained | Buy | Buy |
| Nov 6, 2025 | UBS | Maintained | Buy | Buy |
| Oct 30, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 30, 2025 | RBC Capital | Maintained | Outperform | Outperform |